H1 2024 Financial Results – Steady upward performance
Paiania, 19 September 2024 – Lavipharm reports an increase in consolidated sales in H1 2024. Specifically, consolidated Sales from continuing operations amounted to EUR 30.6 million, compared to EUR 29.1 million in the corresponding period of 2023, for an increase of 5.3%. Consolidated Sales, after...
19 September, 2024